Market Research Logo

Cyclopharm Limited (CYC) - Financial and Strategic SWOT Analysis Review

Cyclopharm Limited (CYC) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Cyclopharm Limited(Cyclopharm) is a radiopharmaceutical company which manufactures medical and healthcare equipment and components in the nuclear medicine business. The company’s products include Technegas, a lung imaging device used to diagnose the presence of blood clots in the lungs; and positron emission tomography (PET) radiopharmaceuticals. The company is evaluating Technegas in new indications such as chronic obstructive pulmonary disease (COPD) and lung cancer. The company operates a joint venture, Macquarie Medical Imaging, which provides diagnostic imaging services such as 3T MRI, CT, X-ray, ultrasound and positron emission tomography (PET) scanning. Cyclopharm harnesses its Ultralute technology, which extends the life of Molybdenum-99 generators. The company operates in Asia Pacific, Canada, Latin America, Europe and Germany. Cyclopharm is headquartered in New South Wales, Australia.

Cyclopharm Limited Key Recent Developments

Feb 24, 2016: Cyclopharm: Strong Technegas Earnings Underpin Record Profit
Oct 12, 2015: Australian company Cyclopharm launches world - first nuclear medicine technolog
Feb 19, 2015: Cyclopharm Reports Record Profit

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Cyclopharm Limited - Key Facts
Cyclopharm Limited - Key Employees
Cyclopharm Limited - Key Employee Biographies
Cyclopharm Limited - Key Operational Employees
Cyclopharm Limited - Major Products and Services
Cyclopharm Limited - History
Cyclopharm Limited - Company Statement
Cyclopharm Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Cyclopharm Limited - Business Description
Cyclopharm Limited - Corporate Strategy
Cyclopharm Limited - SWOT Analysis
SWOT Analysis - Overview
Cyclopharm Limited - Strengths
Strength - Growth in Technegas Segment
Strength - Research and Development Activities
Strength - Operational Base
Cyclopharm Limited - Weaknesses
Weakness - Declined Molecular Imaging Segment
Weakness - Decrease in Canada Geographic Segment
Cyclopharm Limited - Opportunities
Opportunity - Global Diagnostic Imaging Market
Opportunity - Growing Aged Population
Opportunity - Business Initiatives
Cyclopharm Limited - Threats
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
Threat - Rapid Technological Changes
Cyclopharm Limited - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Cyclopharm Limited, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 24, 2016: Cyclopharm: Strong Technegas Earnings Underpin Record Profit
Oct 12, 2015: Australian company Cyclopharm launches world - first nuclear medicine technolog
Feb 19, 2015: Cyclopharm Reports Record Profit
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Cyclopharm Limited, Key Facts
Cyclopharm Limited, Key Employees
Cyclopharm Limited, Key Employee Biographies
Cyclopharm Limited, Key Operational Employees
Cyclopharm Limited, Major Products and Services
Cyclopharm Limited, History
Cyclopharm Limited, Subsidiaries
Cyclopharm Limited, Joint Venture
Cyclopharm Limited, Key Competitors
Cyclopharm Limited, Ratios based on current share price
Cyclopharm Limited, Annual Ratios
Cyclopharm Limited, Interim Ratios
Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Cyclopharm Limited, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Cyclopharm Limited, Performance Chart (2011 - 2015)
Cyclopharm Limited, Ratio Charts
Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report